WHITEHOUSE STATION,  N.J., July 1, 2011 – Merck (NYSE: MRK), known  as MSD outside the United States and Canada,  announced today that the Japanese  Ministry of Health, Labour and Welfare (MHLW) approved three products – GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine,  Recombinant], ZOLINZA® vorinostat) and  CUBICIN® (daptomycin for injection) – […]